ADMA Biologics faces a securities class action alleging violations of federal anti‑fraud statutes, raising legal and investor confidence risks
Executive summary: A class action lawsuit was filed against ADMA Biologics for alleged violations of §§10(b) and 20(a) of the Securities Exchange Act and Rule 10b‑5, accusing the company of misrepresenting its financial condition and revenue. The suit exposes ADMA to potential SEC enforcement, disgorgement, civil penalties and stock price pressure, while highlighting a wave of similar securities filings against other biotech firms.
Who is involved: ADMA Biologics (defendant), DJS Law Group (representing plaintiffs), and unidentified investors; the complaint references alleged channel‑stuffing related to the ASCENIV product.
Likely next: Lead plaintiff must be appointed by the August 10, 2026 deadline, after which the case will proceed to pleadings, possible discovery and settlement discussions.
A class action lawsuit has been filed against ADMA Biologics, alleging that the company violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b‑5 by making false statements about its financial condition and revenue. The complaint cites alleged channel‑stuffing that inflated ASCENIV sales from $92.6 million to $362.5 million over two years. If the claims are substantiated, ADMA could encounter SEC enforcement, financial penalties, and heightened stock volatility.
Timeline
- — ADMA Biologics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ADMA (PR Newswire)
- — GRAIL, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - GRAL (PR Newswire)
- — Embecta Corp. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - EMBC (PR Newswire)
- — SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 10, 2026 in ADMA BIOLOGICS, INC. Lawsuit - ADMA (PR Newswire)
- — Levi & Korsinsky Reminds ADMA BIOLOGICS, INC. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 10, 2026 - ADMA (PR Newswire)
Analysis — what this means
Likely next events
- Lead plaintiff deadline: August 10, 2026 (SueWallSt notice)
Sectors affected
- Biologics manufacturing
- Specialty pharmaceuticals
Regulatory implications
- Potential SEC enforcement under Sections 10(b) and 20(a) of the Securities Exchange Act
Historical parallels
- DJS Law Group filed similar securities class actions against Embecta Corp and GRAIL Inc on July 31, 2026
- Prior ADMA securities filings in July 2026 alleged channel‑stuffing inflated ASCENIV revenue from $92.6 million to $362.5 million over two years
Key entities
Sources
- ADMA Biologics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ADMA — PR Newswire
- GRAIL, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - GRAL — PR Newswire
- Embecta Corp. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - EMBC — PR Newswire
- SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 10, 2026 in ADMA BIOLOGICS, INC. Lawsuit - ADMA — PR Newswire
- Levi & Korsinsky Reminds ADMA BIOLOGICS, INC. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 10, 2026 - ADMA — PR Newswire
Related cases
- Insulet faces a class‑action securities fraud lawsuit with a lead‑plaintiff deadline of August 31, 2026
- Photronics faces class-action securities lawsuit alleging violations of Exchange Act sections 10(b) and 20(a)
- DNOW faces a securities class‑action lawsuit alleging violations of Exchange Act provisions, highlighting ongoing legal risks for the oilfield services distributor
- Genius Group faces class action over alleged securities law violations
- DNOW faces a class action lawsuit alleging securities law violations, raising legal and investor concerns
- Capricor Therapeutics faces a class‑action securities lawsuit alleging violations of exchange‑act provisions, triggering potential legal costs and investor scrutiny